NCT04439292 2026-03-18
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
59 trialsNCT04439318 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439331 2026-03-18
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439357 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05083169 2026-03-18
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05490771 2026-03-18
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06169215 2026-03-18
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06303167 2026-03-18
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06308822 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400238 2026-03-18
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03798678 2026-03-17
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04133636 2026-03-17
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06353022 2026-03-17
IFm2022-01
Nantes University Hospital
Phase 2 Active not recruiting
NCT06390826 2026-03-17
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04181827 2026-03-16
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT03091257 2026-03-13
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT03901963 2026-03-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108195 2026-03-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04722146 2026-03-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06425991 2026-03-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05767359 2026-03-12
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06073353 2026-03-11
THRIVE-M
Massachusetts General Hospital
Phase NA Active not recruiting
NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
NCT00352924 2026-03-06
Agriculture Health Study
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT03844048 2026-03-06
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04656951 2026-03-05
GMMG-DADA
University of Cologne
Phase 2 Active not recruiting
NCT04802356 2026-03-05
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
PETHEMA Foundation
Phase 2 Active not recruiting
NCT05434689 2026-03-05
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03070327 2026-03-04
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT03741127 2026-03-04
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT04108624 2026-03-04
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
University of Chicago
Phase NA Active not recruiting
NCT00602641 2026-03-03
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05271630 2026-03-02
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
H. Lee Moffitt Cancer Center and Research Institute
Active not recruiting
NCT03589222 2026-02-27
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
PETHEMA Foundation
Phase 2 Active not recruiting
NCT04933539 2026-02-27
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT00378105 2026-02-24
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting